Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.
Institute of Pathology, University of Luebeck and University Hospital Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, 23538, Luebeck, Germany.
J Exp Clin Cancer Res. 2022 Feb 2;41(1):46. doi: 10.1186/s13046-022-02255-y.
Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activation is broadly used and continually improved. However, a subset of patients eventually progresses to castration-resistant disease. To date, various mechanisms of resistance have been identified including the development of AR-independent aggressive variant prostate cancer based on neuroendocrine transdifferentiation (NED). Here, we review the highly complex processes contributing to NED. Genetic, epigenetic, transcriptional aberrations and posttranscriptional modifications are highlighted and the potential interplay of the different factors is discussed. Background Aggressive variant prostate cancer (AVPC) with traits of neuroendocrine differentiation emerges in a rising number of patients in recent years. Among others, advanced therapies targeting the androgen receptor axis have been considered causative for this development. Cell growth of AVPC often occurs completely independent of the androgen receptor signal transduction pathway and cells have mostly lost the typical cellular features of prostate adenocarcinoma. This complicates both diagnosis and treatment of this very aggressive disease. We believe that a deeper understanding of the complex molecular pathological mechanisms contributing to transdifferentiation will help to improve diagnostic procedures and develop effective treatment strategies. Indeed, in recent years, many scientists have made important contributions to unravel possible causes and mechanisms in the context of neuroendocrine transdifferentiation. However, the complexity of the diverse molecular pathways has not been captured completely, yet. This narrative review comprehensively highlights the individual steps of neuroendocrine transdifferentiation and makes an important contribution in bringing together the results found so far.
前列腺癌是一种激素驱动的疾病,其肿瘤细胞的生长高度依赖于雄激素受体 (AR) 信号的增强。因此,针对雄激素合成或 AR 激活的靶向治疗被广泛应用并不断改进。然而,一部分患者最终会发展为去势抵抗性疾病。迄今为止,已经确定了各种耐药机制,包括基于神经内分泌转化 (NED) 的 AR 独立侵袭性前列腺癌变体的发展。在这里,我们回顾了促成 NED 的高度复杂过程。强调了遗传、表观遗传、转录异常和转录后修饰,并讨论了不同因素的潜在相互作用。背景 近年来,具有神经内分泌分化特征的侵袭性变异型前列腺癌 (AVPC) 在越来越多的患者中出现。其中,针对雄激素受体轴的先进治疗方法被认为是导致这种发展的原因之一。AVPC 的细胞生长通常完全独立于雄激素受体信号转导途径,并且细胞大多失去了前列腺腺癌的典型细胞特征。这使得这种非常侵袭性疾病的诊断和治疗变得复杂。我们相信,深入了解促成转化的复杂分子病理机制将有助于改进诊断程序并开发有效的治疗策略。事实上,近年来,许多科学家在神经内分泌转化的背景下做出了重要贡献,以揭示可能的原因和机制。然而,多样化分子途径的复杂性尚未完全被捕获。这篇叙述性综述全面强调了神经内分泌转化的各个步骤,并在汇集迄今为止发现的结果方面做出了重要贡献。